RXDX Insider Trading Activity and SEC Form 4 Filings
RXDX insider trading summary
No open-market insider purchases or sales of Prometheus Biosciences, Inc. (RXDX) have been reported on SEC Form 4 in the past 12 months.
Latest RXDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 5, 2023 | Keith W Marshall | Chief Financial Officer | Sell | $1.1M (10,000 @ $108.42) |
| Mar 15, 2023 | Mark C. McKenna | Chairman, President & CEO | Sell | $2.9M (25,000 @ $116.14) |
| Mar 8, 2023 | Cedars Sinai Intellectual Property Co | 10% Owner | Sell | $99.1M (865,000 @ $114.59) |
| Mar 6, 2023 | Keith W Marshall | Chief Financial Officer | Sell | $1.2M (10,000 @ $122.13) |
| Mar 3, 2023 | Mark C. McKenna | Chairman, President & CEO | Sell | $1.3M (10,620 @ $125.13) |
| Mar 1, 2023 | Mark C. McKenna | Chairman, President & CEO | Sell | $88K (700 @ $125.26) |
| Feb 17, 2023 | Mark C. McKenna | Chairman, President & CEO | Sell | $1.7M (13,680 @ $125.10) |
| Feb 16, 2023 | Mark C. McKenna | Chairman, President & CEO | Sell | $3.0M (25,000 @ $119.87) |
| Feb 15, 2023 | Keith W Marshall | Chief Financial Officer | Sell | $597K (5,000 @ $119.38) |
| Feb 15, 2023 | Mark C. McKenna | Chairman, President & CEO | Sell | $3.0M (25,000 @ $119.42) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.